NEW YORK, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a securities class action lawsuit on behalf of shareholders who bought shares of Abeona Therapeutics Inc. (ABEO) between May 31, 2018 and September 23, 2019, inclusive (the “Class Period”).
If you wish to serve as lead plaintiff, you must move the Court no later than January 2, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the case go to http://zhanginvestorlaw.com/join-action-form/?slug=abeona-therapeutics-inc&id=2090or to discuss your rights or interests regarding this class action, please contact Sophie Zhang, Esq. or Spencer Lee toll-free at 800-991-3756 or email firstname.lastname@example.org, email@example.com for information on the class action.
According to the case, defendants made false and/or misleading statements and/or failed to disclose that (1) Abeona’s Chemical, Manufacturing and Controls and internal controls and procedures and/or compliance policies were inadequate; (2) the Company failed to provide sufficient data points on the transport stability of EB-101 to clinical sites, or such transport stability was insufficient; (3) it was foreseeable that the U.S. Food and Drug Administration would reject approval for the start of the VITAL Study until such issues were addressed; and (4) as a result, Abeona’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class has not been certified. You may retain counsel of your choice. You may take no action at this time and be an absent class member. Your ability to obtain a recovery is not dependent upon being a lead plaintiff.
Zhang Investor Law represents investors worldwide. Attorney Advertising. Prior results do not guarantee similar outcomes.
Zhang Investor Law P.C.
99 Wall Street, Suite 232
New York, New York 10005
tel: (800) 991-3756